Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

Neovasc (TSX:NVCN; NASDAQ:NVCN) has announced the first US patient has been implanted with NEovasc Reducer, a medical device for the treatment of refractory angina.

As quoted in the press release:

The Compassionate Use case was conducted by Dr. Gerald Koenig, along with Dr. Ryan Gindi and colleagues, of the Division of Cardiology at Henry Ford Hospital in Detroit, Michigan.

Dr. Koenig commented “This patient has severe coronary artery disease and has suffered from refractory angina for a few years. The condition has had a significant impact on his quality of life during this time, with little to no relief from multiple other widely accepted treatment options.”

“This novel device has accumulating evidence supporting the physiological basis and associated clinical benefit. My experience with the Reducer during the procedure, was very positive. The process is similar to implanting a stent. In terms of the patient, he tolerated the procedure very well and had no complications,” concluded Dr. Koenig.

“We are pleased to provide this patient the opportunity to receive a Reducer implanted under Compassionate Use. As our studies and patients in multiple geographies, including Europe, Israel and Saudi Arabia, have shown, this device offers angina sufferers the potential to improve exercise capacity and resume a normal life, free of the pain and discomfort that has often limited their ability to perform normal daily activities,” commented Fred Colen, Neovasc’s President and Chief Executive Officer. “The Reducer continues to gain attention from medical professionals around the world as the number of patient cases have increased with the scaling of our commercial activities.”

Click here to read the full press release.